Navigation Links
Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Company's Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
Date:8/28/2012

BOULDER, Colo., Aug. 28, 2012 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today publication of preclinical research demonstrating utility of interleukin-11 (IL-11) and the company's long-acting IL-11 analog to prevent kidney damage from ischemia reperfusion injury in mice.  This work may lead to new therapeutic approaches to prevent acute kidney injury and ischemia reperfusion injury to multiple organ types. 

The studies were performed in the laboratory of H. Thomas Lee, M.D., Ph.D., Professor and Director of Transplantation Anesthesiology, Department of Anesthesiology, Columbia University, New York, and published as an Advance Online Publication in the American Journal of Physiology – Renal Physiology (http://ajprenal.physiology.org; published ahead of print August 1, 2012, doi:10.1152/ajprenal.00220.2012).

George (Joe) Cox, Ph.D., Company President stated "IL-11 is a multifunctional protein that is used clinically to treat thrombocytopenia (low platelet counts) in cancer patients receiving chemotherapy. Dr. Lee's experiments show for the first time that IL-11 also can prevent kidney damage that results when blood flow to the kidneys is temporarily blocked and then restarted (ischemia-reperfusion), such as occurs during many types of major surgeries. Restoring blood flow to the ischemic kidney initiates an inflammatory response that damages the healthy kidney and can lead to acute kidney injury and renal failure.  Renal ischemia-reperfusion injury is a major clinical problem that is associated with a high incidence of permanent kidney damage and high mortality in certain patient populations. There are no effective therapies for reducing the incidence of surgery-associated acute kidney injury.  Dr. Lee's studies showed that administration of IL-11 or our biosuperior, long-acting IL-11 analog prior to, or shortly after renal ischemia-reperfusion preserved kidney function and significantly reduced the amount of kidney cell necrosis, cell death and inflammation compared to a placebo. Dr. Lee's studies also elucidated the intracellular signaling pathways triggered by IL-11 that are responsible for protecting the kidney from ischemia-reperfusion injury.

This research was supported by grants from the National Institutes of Health to Dr. H. Thomas Lee and to Bolder Biotechnology, Inc.

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. For additional information about Bolder BioTechnology, Inc., please visit our web site at www.bolderbio.com.

Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties.  There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company.  These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.


'/>"/>
SOURCE Bolder BioTechnology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Puma Biotechnology Announces Completion of Private Placement
2. Animal Biotechnology - Technologies, Markets and Companies
3. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
4. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
5. JumpStart Invests $250,000 in Milo Biotechnology
6. Global Biotechnology Industry
7. Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
8. Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
9. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
10. Global Biotechnology Instrumentation Industry
11. Choose New Jersey, Inc. to Tout New Jerseys Life Sciences Hub At Worlds Largest Biotechnology Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):